Erbitux Hearing May Feature FDA Reviewer Communication Policies
Executive Summary
The House Energy & Commerce Committee's Oct. 10 follow-up hearing on the Erbitux (cetuximab) BLA may serve as a venue to discuss FDA's internal policy on communication between reviewers and sponsors over pending applications
You may also be interested in...
CBER Oncology Group Will Work To Create Consistent Approach To Products
The Office of Cellular, Gene & Tissue Therapies' new oncology group will work to ensure coordination in approaches to oncology products throughout FDA
CBER Oncology Group Will Work To Create Consistent Approach To Products
The Office of Cellular, Gene & Tissue Therapies' new oncology group will work to ensure coordination in approaches to oncology products throughout FDA
FDA Emphasizing Written Communication With Sponsors On Pending NDAs
FDA will emphasize official written action letters in its internal policy on communication with sponsors drafted in response to the Congressional investigation of the Erbitux review, Acting Commissioner Crawford said Oct. 10